



GENFIT ANNOUNCES DEPARTURE OF COO AND A MEMBER OF THE MANAGEMENT BOARD FLORENCE SEJOURNE FOR CEO POSITION IN A BIOTECH START-UP

Lille (France), Cambridge (Mass.), May 28, 2008 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111) a biopharmaceutical company at the forefront of research and development of cardiovascular, inflammatory and metabolic drugs today announced that Florence Séjourné, Executive Vice President and Chief Operating Officer and also a Member of the Management Board is leaving the company to accept a position as Chief Executive Officer of a start-up biotech company. In complete agreement with GENFIT, Florence Séjourné will continue to serve the Chairman and the Management of the Company in an advisory capacity.

“With the arrival of new members of the management team in scientific departments and business development, GENFIT has reached the excellence level that we had targeted within the founding members. Today, GENFIT has assembled a recognized leadership team in the field of the cardiovascular diseases with a promising outlook for discovering therapeutic innovations to address significant unmet medical needs in the cardiometabolic and CNS fields” stated Florence Séjourné.

Jean-François Mouney, Chairman of GENFIT’s Management Board, concluded: “On behalf of all the employees at GENFIT, I would like to thank Florence very much for all the enthusiasm she has brought to GENFIT over the past 10 years. She has been one of the key figures in the establishment of our industrial partnerships, which constitutes as one of the key factors in GENFIT’s success. On a personal note, I wish her all the success in her new exciting endeavor”.

About GENFIT:

A biopharmaceutical company, GENFIT studies the deregulation of genes implicated in many of the most widespread diseases. GENFIT’s scientists identify new therapeutic targets and develop drug candidates designed specifically for such targets. GENFIT’s programs, conducted in partnership with pharmaceutical companies such as SANOFI-AVENTIS, SOLVAY GROUP, PIERRE FABRE, MERCK AG, and SERVIER, treat the most prevalent metabolic and inflammatory diseases. GENFIT’s development of proprietary drugs focuses on global cardiovascular risk factors, using a single molecule to simultaneously attack several pathologies (atherosclerosis, diabetes, obesity, etc.).

GENFIT possesses a rich and diversified pipeline of drug candidates in all stages of development – development carried out by GENFIT alone or in partnership. GENFIT’s lead proprietary compound, GFT505, is currently in Phase II and another compound in partnership with SANOFI-AVENTIS (AVE0897) is now completing Phase I. With facilities in Lille, France, and Cambridge, MA (USA), the company has over 130 employees on staff, including over 100 scientists. GENFIT is a public company listed on the Alternext by EuronextTM Paris (Alternext: ALGFT; ISIN: FR0004163111). (www.genfit.com).

Contacts:

GENFIT

Investors Relations + 33 (0) 3 2016 4000

Investors@Genfit.com

Milestones – Press Relations

Bruno Arabian +33 (0)1 70 08 04 13 / +33 (0) 6 87 88 47 26 - milestones@milestones-fr.com

Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company’s actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company’s prospectus.